Delta inulin: A novel, immunologically active, stable packing structure comprising β-D-[2 → 1] poly(fructo-furanosyl) αd-glucose polymers

Glycobiology

Volumn 21, Issue 5, 2011, Pages 595-606

  Cooper, Peter D ^a,b   Petrovsky, Nikolai ^a  

^a VAXINE PTY LTD   (Australia)

^b The Australian National University   (Australia)

Author keywords

adjuvant; carbohydrate; inulin; isoform; vaccine

Indexed keywords

ALPHA INULIN; BETA DEXTRO[2-1]POLY(FRUCTO FURANOSYL)ALPHA DEXTRO GLUCOSE POLYMER; BETA INULIN; CELL SURFACE PROTEIN; CHEMOKINE; COMPLEMENT; DELTA INULIN; DIMETHYL SULFOXIDE; GAMMA INULIN; GLUCOSE POLYMER; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; INULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HEAT TREATMENT; HUMORAL IMMUNITY; HYDROGEN BOND; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MONOCYTE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TEMPERATURE; TEMPERATURE SENSITIVITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; COMPLEMENT ACTIVATION; DAHLIA; HUMANS; IMMUNE SERA; INULIN; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MONOCYTES; NANOPARTICLES; PARTICLE SIZE; PLANT EXTRACTS; PLANT TUBERS; SOLUBILITY;

EID: 79953874296     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwq201     Document Type: Article

References (34)

1. André I, Mazeau K, Tvaroska I, Putaux J-L, Winter WT, Taravel FR, Chanzy H. 1996. Molecular and crystal structures of inulin from electron diffraction data. Macromolecules. 29:4626-4635. (Pubitemid 126520430)
2. André I, Putaux J-L, Chanzy H, Taravel FR, Timmermans JW, de Wit D. 1996. Single crystals of inulin. Int J Biol Macromol. 18:195-204. (Pubitemid 26079746)
3. Arvieux J, Yssel H, Colomb MG. 1988. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology. 65(2):229-235.
4. Aziz BH, Chin B, Deacon MP, Harding SE, Pavlov GM. 1999. Size and shape of inulin in dimethyl sulphoxide solution. Carbohydr Polym. 38:231-234.
5. Cooper PD, Carter M. 1986a. Anticomplementary action of polymorphic 'solubility forms' of particulate inulin. Mol Immunol. 23:895-901. (Pubitemid 16057598)
6. Cooper PD, Carter M. 1986b. The anti-melanoma activity of inulin in mice. Mol Immunol. 23:903-908. (Pubitemid 16057599)
7. Cooper PD, Steele EJ. 1988. The adjuvanticity of gamma inulin. Immunol Cell Biol. 66:345-352. (Pubitemid 19050890)
8. Cooper PD, Steele EJ. 1991. Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: Preparation and in vitro properties. Vaccine. 9:351-357.
9. Cooper PD, Turner R, McGovern J. 1991. Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice. Immunol Lett. 27:131-134.
10. De Leenheer L, Hoebregs H. 1994. Progress in the elucidation of the composition of chicory inulin. Starch. 46:193-196.
11. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. 1996. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science. 271(5247):348-350.
12. Dona A, Yuen C-WW, Peate J, Gilbert RG, Castignolles P, Gaborieau M. 2007. A new NMR method for directly monitoring and quantifying the dissolution kinetics of starch in DMSO. Carbohydr Res. 342:2604-2610. (Pubitemid 350011087)
13. Frazer IH, Tindle RW, Fernando GJP, Malcolm K, Herd K, McFadyn S, Cooper PD, Ward B. 1999. Safety and immunogenicity of HPV16 E7/ Algammulin. In: Tindle RW, editor. Vaccines for Human Papillomavirus Infection and Anogenital Disease. New York (USA): RG Landes. p 91-104.
14. Fuentes P, Cooper PD, Barnadas R, Sabés M, Osterhoff C, Martínez P. 2003. Use of γ inulin/liposomes/vitamin-E adjuvant in contraceptive vaccines. Int J Pharmaceutics. 7445:1-11.
15. Götze O, Müller-Eberhard HJ. 1971. The C3 activator system: An alternative pathway of complement activation. J Exp Med. 134:90S-108S.
16. Hoffmann LG, Mayer MM. 1977. Immune hemolysis and complement fixation. In: Williams CA, Chase MW, editors. Methods in Immunology and Immunochemistry. Vol. 4. New York (USA): Academic Press. p. 137-166.
17. Kerekis K, Cooper PD, Prechi J, Józsi M, Bajtay Z, Erdei A. 2001. Adjuvant effect of γ-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J Leukoc Biol. 69:69-74. (Pubitemid 32095119)
18. Korbelik M, Cooper PD. 2007. Potentiation of photodynamic therapy of cancer by complement: The effect of gamma-inulin. Br J Cancer. 96:67-72. (Pubitemid 46094641)
19. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, Toriniwa H, Petrovsky N. 2010. An inactivated Vero cell-grown Japanese encephalitis 1 vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralising antibody against homologous and heterologous fla-viviruses. J Gen Virol. 91:1407-1417.
20. McDonald EJ. 1946. The polyfructosans and difructose anhydrides. Adv Carbohyd Chem. 2:253-277.
21. Meri S, Pangburn M. 1990. Discriminators between activators and non-activators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA. 87:3982-3986.
22. Müller-Eberhard HJ. 1988. Molecular organization and function of the complement system. Ann Rev Biochem. 57:321-347.
23. Müller-Eberhard HJ, Schreiber RD. 1980. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol. 29:1-55.
24. Oscarson S, Sehgelmebel FW. 2002. Chemical syntheses of inulin and levan structures. J Org Chem. 67:8457-8462. (Pubitemid 35402994)
25. Pace CN, Shirley BA, McNutt M, Gajiwala K. 1996. Forces contributing to the conformational stability of proteins. FASEB J. 10:75-83. (Pubitemid 26035509)
26. Pangburn MK, Ferreira VP, Cortes C. 2008. Discrimination between host and pathogens by the complement system. Vaccine. 26S8:115-121.
27. Pangburn MK, Müller-Eberhard HJ. 1984. The alternative pathway of complement. Springer Semin Immunopathol. 7:163-192. (Pubitemid 14010635)
28. Phelps CF. 1965. The physical properties of inulin solutions. Biochem J. 95:41-47.
29. Radosta S, Haberer M, Vorwerg W. 2001. Molecular characteristics of amylose and starch in dimethyl sulfoxide. Biomacromolecules. 2:970-978. (Pubitemid 32894658)
30. Sahu A, Kozel TR, Pangburn MK. 1994. Specificity of the thioester-containing site of human C3 and its significance to complement activation. Biochem J. 302:429-436. (Pubitemid 24280095)
31. Silva DG, Cooper PD, Petrovsky N. 2004. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol. 82:611-616. (Pubitemid 39563962)
32. Stephen AM. 1983. Other plant polysaccharides. In: Aspinall GO, editor. The Polysaccharides. Vol. 2. New York (USA): Academic Press. p. 97-193.
33. Ward PA. 1967. A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med. 126:189-206.
34. Zipfel PF, Hallström T, Hammerschmidt S, Skerka C. 2008. The complement fitness factor H: Role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine. 268:167-174.